Financial Result for the financial year ending March 31, 2025 Board meeting held on May 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Coral Laboratories reported audited standalone results for FY25 with revenue from operations rising 37.5% YoY to ₹11,500.53 lakhs (vs ₹8,366.04 lakhs in FY24). Total income grew to ₹12,411.39 lakhs. Profit before exceptional items and tax jumped 59% to ₹3,323.98 lakhs, while profit after tax grew 53% to ₹2,415.56 lakhs (vs ₹1,578.90 lakhs). EPS rose to ₹67.61 from ₹44.19. The board recommended a 15% final dividend (₹1.50 per share on ₹10 face value). Q4 PAT of ₹282.71 lakhs was significantly lower than Q3 FY25 (₹614.45 lakhs) due to a ₹76.96 lakh exceptional item for earlier-year tax provision. The statutory auditor issued an unmodified opinion. Reserves stood at ₹19,763.32 lakhs, and operating cash flow turned positive at ₹733.15 lakhs (vs ₹488.47 lakhs).
Strong full-year performance with healthy revenue and profit growth, supported by a positive dividend and clean audit opinion, is positive for shareholders. However, the sharp sequential drop in Q4 PAT due to the one-time tax provision may draw short-term attention from investors.